NasdaqGM:AUPHBiotechs
Aurinia Pharmaceuticals (AUPH) Earnings Spike Above Revenue Challenges Profit Quality Narratives
Aurinia Pharmaceuticals (AUPH) closed FY 2025 with Q4 revenue of US$77.1 million and basic EPS of US$1.60, alongside trailing twelve month EPS of US$2.14 on revenue of US$283.1 million. This frames a very strong headline earnings story. Over the past few quarters, the company has seen revenue move from US$59.9 million in Q4 2024 to US$77.1 million in Q4 2025, while quarterly EPS shifted from roughly breakeven at US$0.01 to US$1.60, with trailing twelve month net income reaching US$287.2...